Hong Zhu
Zhejiang University
384 Papers
1.1K Citations
Hong Zhu is an academic researcher from Zhejiang University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 49, co-authored 323 publications. Previous affiliations of Hong Zhu include Center for Excellence in Education & Shanghai Jiao Tong University.
Chat about Author
Papers
Crystal structural evolution and hybrid improper ferroelectricity in Ruddlesden-Popper Ca3-xSrxTi2O7 ceramics
TL;DR: In this paper, a hybrid improper ferroelectricity (HIF) has been proposed as a candidate approach to create room-temperature multiferroic materials with an intrinsic electric-field controlled magnetism effect, and HIFs in bi-layered Ruddlesden-Popper Ca3-xSrxTi2O7 ceramics have been confirmed.
40
Role of Protein Misfolding in DFNA9 Hearing Loss
TL;DR: It is demonstrated that mutant cochlin, the protein product of the COCH gene, forms a stable dimer that is sensitive to reducing agent and is cytotoxic in vitro and in vivo and provides an in vitro model that may be used to explore protein-misfolding diseases in general.
40
Reduction of mNAT1/hNAT2 Contributes to Cerebral Endothelial Necroptosis and Aβ Accumulation in Alzheimer's Disease.
Chengyu Zou,Lauren Mifflin,Zhirui Hu,Tian Zhang,Bing Shan,H. Wang,Xin Xing,Hong Zhu,Xian Adiconis,Joshua Z. Levin,Fupeng Li,Chuan-Fa Liu,Jun Liu,Junying Yuan +13 more
TL;DR: Selective restoration of cerebral EC expression of mNAT1 delivered by adeno-associated virus rescues cerebromicrovascular levels of A20 and LRP1β, inhibits endothelial necroptosis and activation, ameliorates mitochondrial fragmentation, reduces Aβ deposits, and improves cognitive function in the AD mouse model.
40
Targeting post-translational modification of transcription factors as cancer therapy
TL;DR: This review systematically review emerging concepts and effective agents in PTMs-associated TF-targeting, which could provide paradigms for cancer treatment.
40
Drug Combination in Clinical Cancer Treatments.
TL;DR: These types of cancer therapeutic management systems for clinical anticancer drug combination utilities are addressed and future cancer drug combinational studies and clinical optimums must be implemented.
39